

Carmela Pinnetti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7827302/publications.pdf>

Version: 2024-02-01

92
papers

1,157
citations

430442

18
h-index

500791

28
g-index

93
all docs

93
docs citations

93
times ranked

1968
citing authors

#	ARTICLE	IF	CITATIONS
1	Minimal prevalence of HPV vaccination and common occurrence of high-risk HPV types in pregnant women with HIV: data from a national study in Italy. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2022, 41, 505-509.	1.3	0
2	Use of Pembrolizumab for Treatment of Progressive Multifocal Leukoencephalopathy in People Living with HIV. <i>Viruses</i> , 2022, 14, 970.	1.5	3
3	COVID-19 in people living with HIV: Clinical implications of dynamics of the immune response to SARS-CoV-2. <i>Journal of Medical Virology</i> , 2021, 93, 1796-1804.	2.5	38
4	Molecular Transmission Dynamics of Primary HIV Infections in Lazio Region, Years 2013-2020. <i>Viruses</i> , 2021, 13, 176.	1.5	4
5	Spontaneous ilio-psoas haematomas (IPHs): a warning for COVID-19 inpatients. <i>Annals of Medicine</i> , 2021, 53, 295-301.	1.5	33
6	Risk and predictive factors of prolonged viral RNA shedding in upper respiratory specimens in a large cohort of COVID-19 patients admitted to an Italian reference hospital. <i>International Journal of Infectious Diseases</i> , 2021, 105, 532-539.	1.5	20
7	CD4/CD8 ratio in pregnant women with HIV and its association with pregnancy outcome: data from a national study in Italy. <i>Infection</i> , 2021, 49, 955-964.	2.3	0
8	Role of testosterone in SARS-CoV-2 infection: A key pathogenic factor and a biomarker for severe pneumonia. <i>International Journal of Infectious Diseases</i> , 2021, 108, 244-251.	1.5	29
9	Impact of Direct-Acting Antivirals on the Outcome of HIV/HCV Coinfected Patients with Non-Hodgkin Lymphomas in the Modern Anti-Retroviral Therapy Era: A Retrospective Multicenter Study of 74 Cases. <i>Blood</i> , 2021, 138, 1434-1434.	0.6	0
10	Impact of ART on dynamics of growth factors and cytokines in primary HIV infection. <i>Cytokine</i> , 2020, 125, 154839.	1.4	12
11	SARS-CoV-2 infection does not induce HIV viral escape in the central nervous system: A case series. <i>International Journal of Infectious Diseases</i> , 2020, 101, 38-41.	1.5	4
12	The dual-target approach in viral HIV-1 viremia testing: An added value to virological monitoring?. <i>PLoS ONE</i> , 2020, 15, e0228192.	1.1	6
13	Effect of HIV-infection on QuantiFERON-plus accuracy in patients with active tuberculosis and latent infection. <i>Journal of Infection</i> , 2020, 80, 536-546.	1.7	38
14	Prevalence, Correlates and Outcomes of Smoking in Pregnant Women with HIV: A National Observational Study in Italy. <i>Substance Use and Misuse</i> , 2020, 55, 1165-1172.	0.7	4
15	Weight Gain during Pregnancy in Women with HIV Receiving Different Antiretroviral Regimens. <i>Antiviral Therapy</i> , 2020, 25, 315-325.	0.6	4
16	Enhanced Immunological Recovery With Early Start of Antiretroviral Therapy During Acute or Early HIV Infection-Results of Italian Network of ACuTe HIV Infection (INACTION) Retrospective Study. <i>Pathogens and Immunity</i> , 2020, 5, 8.	1.4	16
17	Myeloid Derived Suppressor Cells Expansion Persists After Early ART and May Affect CD4 T Cell Recovery. <i>Frontiers in Immunology</i> , 2019, 10, 1886.	2.2	15
18	In Human Immunodeficiency Virus primary infection, early combined antiretroviral therapy reduced T cell activation but failed to restore their polyfunctionality. <i>Immunology</i> , 2019, 157, 322-330.	2.0	6

#	ARTICLE	IF	CITATIONS
19	Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm ³ and HIV-RNA >5 log ₁₀ copies/mL. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2732-2741.	1.3	11
20	Vitamin D deficiency is associated with neurocognitive impairment in HIV-infected subjects. <i>Infection</i> , 2019, 47, 929-935.	2.3	6
21	Characterisation of HIV-1 molecular transmission clusters among newly diagnosed individuals infected with non-B subtypes in Italy. <i>Sexually Transmitted Infections</i> , 2019, 95, 619-625.	0.8	18
22	Very High Pre-Therapy Viral Load is a Predictor of Virological Rebound in HIV-1-Infected Patients Starting a Modern First-Line Regimen. <i>Antiviral Therapy</i> , 2019, 24, 321-331.	0.6	4
23	Cerebrospinal fluid HIV-1 escape according to different thresholds and underlying comorbidities. <i>Aids</i> , 2019, 33, 759-762.	1.0	19
24	Randomized clinical trial on efficacy of fixed-dose efavirenz/tenofovir/emtricitabine on alternate days versus continuous treatment. <i>Aids</i> , 2019, 33, 493-502.	1.0	6
25	Viro-Immunological Response of Drug-Naive HIV-1-Infected Patients Starting a First-Line Regimen with Viraemia >500,000 Copies/ml in Clinical Practice. <i>Antiviral Therapy</i> , 2018, 23, 249-257.	0.6	10
26	Impact of antiretroviral and tuberculosis therapies on CD4 + and CD8 + HIV/M. tuberculosis-specific T-cell in co-infected subjects. <i>Immunology Letters</i> , 2018, 198, 33-43.	1.1	21
27	IL-18 and Stem Cell Factor affect hematopoietic progenitor cells in HIV-infected patients treated during primary HIV infection. <i>Cytokine</i> , 2018, 103, 34-37.	1.4	8
28	Prevalence and Associated Factors of Neurocognitive Impairment in HIV-Positive Patients on Effective Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Treatment. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 907-908.	0.5	5
29	Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment. <i>Journal of Clinical Virology</i> , 2018, 104, 61-64.	1.6	19
30	Amniocentesis and chorionic villus sampling in HIV-infected pregnant women: a multicentre case series. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2017, 124, 1218-1223.	1.1	14
31	Virological response and resistance profile in HIV-infected patients starting darunavir-containing regimens. <i>HIV Medicine</i> , 2017, 18, 21-32.	1.0	9
32	Immune characterization of the HBHA-specific response in Mycobacterium tuberculosis-infected patients with or without HIV infection. <i>PLoS ONE</i> , 2017, 12, e0183846.	1.1	31
33	Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients. <i>PLoS ONE</i> , 2017, 12, e0171611.	1.1	10
34	Slow or fast viral load decay as a predictor of residual viremia level in HIV-infected patients undergoing successful first-line cART. <i>New Microbiologica</i> , 2017, 40, 234-241.	0.1	0
35	HCV-HIV coinfecting pregnant women: data from a multicentre study in Italy. <i>Infection</i> , 2016, 44, 235-242.	2.3	19
36	The diabetes-tuberculosis co-epidemic: the role of international migration. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016, 20, 771-777.	0.6	5

#	ARTICLE	IF	CITATIONS
37	Extratemporal herpes encephalitis during natalizumab treatment: A case report. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 10, 134-136.	0.9	7
38	The HIV-1 reverse transcriptase polymorphism A98S improves the response to tenofovir disoproxil fumarate+emtricitabine-containing HAART both in vivo and in vitro. <i>Journal of Global Antimicrobial Resistance</i> , 2016, 7, 1-7.	0.9	3
39	Pregnancy outcomes and cytomegalovirus DNAemia in HIV-infected pregnant women with CMV. <i>Clinical Microbiology and Infection</i> , 2016, 22, 818-820.	2.8	2
40	Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the IcoNa Foundation Cohort. <i>PLoS ONE</i> , 2016, 11, e0156360.	1.1	0
41	Successful prevention of HIV mother-to-child transmission with dolutegravir-based combination antiretroviral therapy in a vertically infected pregnant woman with multiclass highly drug-resistant HIV-1. <i>Aids</i> , 2015, 29, 2534-2537.	1.0	16
42	Good prenatal detection rate of major birth defects in HIV-infected pregnant women in Italy. <i>Prenatal Diagnosis</i> , 2015, 35, 1374-1378.	1.1	3
43	Recent Transmission Clustering of HIV-1 C and CRF17_BF Strains Characterized by NNRTI-Related Mutations among Newly Diagnosed Men in Central Italy. <i>PLoS ONE</i> , 2015, 10, e0135325.	1.1	21
44	Is "Option B+" Also Being Adopted in Pregnant Women in High-Income Countries? Temporal Trends From a National Study in Italy. <i>Clinical Infectious Diseases</i> , 2015, 60, 159-161.	2.9	3
45	Immune Status and Serial Quantiferon-TB Gold In-Tube Screening for Latent <i>Mycobacterium tuberculosis</i> Infection Among HIV-Infected Persons in a Country With a Low Tuberculosis Incidence. <i>Journal of Infectious Diseases</i> , 2015, 211, 1852-1853.	1.9	5
46	Full Viral Suppression, Low-Level Viremia, and Quantifiable Plasma HIV-RNA at the End of Pregnancy in HIV-Infected Women on Antiretroviral Treatment. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 673-678.	0.5	1
47	Genotypic Tropism Testing in HIV-1 Proviral DNA Can Provide Useful Information at Low-Level Viremia. <i>Journal of Clinical Microbiology</i> , 2015, 53, 2935-2941.	1.8	6
48	Early ART in primary HIV infection may also preserve lymphopoiesis capability in circulating haematopoietic progenitor cells: a case report. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1598-1600.	1.3	6
49	HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1865-1873.	1.3	23
50	An anal cancer screening program for MSM in Italy: Prevalence of multiple HPV types and vaccine-targeted infections. <i>Journal of Clinical Virology</i> , 2015, 72, 49-54.	1.6	14
51	Randomized trial of DRV/r or LPV/r QD monotherapy vs maintaining a PI/r-based antiretroviral regimen in persons with suppressed HIV replication. <i>Journal of the International AIDS Society</i> , 2014, 17, 19809.	1.2	2
52	Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort. <i>Journal of the International AIDS Society</i> , 2014, 17, 19812.	1.2	17
53	Relationship between body mass index and bone mineral density in HIV-infected patients referred for DXA. <i>Journal of the International AIDS Society</i> , 2014, 17, 19569.	1.2	9
54	APRI and FIB-4 scores are not associated with neurocognitive impairment in HIV-infected persons. <i>Journal of the International AIDS Society</i> , 2014, 17, 19658.	1.2	0

#	ARTICLE	IF	CITATIONS
55	Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis. <i>Journal of the International AIDS Society</i> , 2014, 17, 19802.	1.2	2
56	Rate, Predictors, and Consequences of Late Antenatal Booking in a National Cohort Study of Pregnant Women With HIV in Italy. <i>HIV Clinical Trials</i> , 2014, 15, 104-115.	2.0	11
57	Pregnancy Outcomes Among ART-Naive and ART-Experienced HIV-Positive Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 67, 258-267.	0.9	4
58	Reliability and Clinical Relevance of the HIV-1 Drug Resistance Test in Patients With Low Viremia Levels. <i>Clinical Infectious Diseases</i> , 2014, 58, 1156-1164.	2.9	67
59	Polyfunctional T-cells and effector memory phenotype are associated with active TB in HIV-infected patients. <i>Journal of Infection</i> , 2014, 69, 533-545.	1.7	90
60	Atazanavir and lopinavir profile in pregnant women with HIV: tolerability, activity and pregnancy outcomes in an observational national study. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1377-1384.	1.3	13
61	Central nervous system penetration effectiveness rank does not reliably predict neurocognitive impairment in HIV-infected individuals. <i>Journal of the International AIDS Society</i> , 2014, 17, 19655.	1.2	13
62	Acute HIV infection (AHI) in a specialized clinical setting: case-finding, description of virological, epidemiological and clinical characteristics. <i>Journal of the International AIDS Society</i> , 2014, 17, 19676.	1.2	3
63	Circulation of HIV-1 CRF02_AG among MSM Population in Central Italy: A Molecular Epidemiology-Based Study. <i>BioMed Research International</i> , 2013, 2013, 1-8.	0.9	11
64	Body Mass Index and Weight Gain in Pregnant Women With HIV: A National Study in Italy. <i>Clinical Infectious Diseases</i> , 2013, 56, 1190-1193.	2.9	0
65	Birth defects in a national cohort of pregnant women with HIV infection in Italy, 2001-2011. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2013, 120, 1466-1476.	1.1	34
66	Impact of Pre-Therapy Viral Load on Virological Response to Modern First-Line Haart. <i>Antiviral Therapy</i> , 2013, 18, 867-876.	0.6	34
67	Durability of Lopinavir/ritonavir mono-therapy in individuals with viral load ≤ 50 copies/mL in the observational setting. <i>Antiviral Therapy</i> , 2013, 19, 319-324.	0.6	5
68	Pregnancy Outcomes in HIV-Infected Women of Advanced Maternal Age. <i>HIV Clinical Trials</i> , 2013, 14, 110-119.	2.0	4
69	Viral, host and therapeutic factors affecting T-cell recovery in virologically controlled HIV patients. <i>Future Virology</i> , 2012, 7, 911-921.	0.9	1
70	Use of Specific Antiretroviral Regimens Among HIV-Infected Women in Italy at Time of Conception: 2001-2011. <i>AIDS Patient Care and STDs</i> , 2012, 26, 439-443.	1.1	7
71	Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy. <i>American Journal of Hematology</i> , 2012, 87, 749-753.	2.0	24
72	Glucose Plasma Levels and Pregnancy Outcomes in Women with HIV. <i>HIV Clinical Trials</i> , 2011, 12, 299-312.	2.0	1

#	ARTICLE	IF	CITATIONS
73	Hematological effects of zidovudine prophylaxis in newborn infants with and without prenatal exposure to zidovudine. <i>Journal of Medical Virology</i> , 2011, 83, 551-556.	2.5	13
74	Common occurrence of anaemia at the end of pregnancy following exposure to zidovudine-free regimens. <i>Journal of Infection</i> , 2011, 63, 144-150.	1.7	3
75	Rubella Susceptibility Profile in Pregnant Women with HIV. <i>Clinical Infectious Diseases</i> , 2011, 52, 960-962.	2.9	5
76	Pregnancy Outcomes in Women with Advanced HIV Infection in Italy. <i>AIDS Patient Care and STDs</i> , 2011, 25, 639-645.	1.1	13
77	Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1. <i>Antiviral Therapy</i> , 2010, 15, 127-129.	0.6	11
78	Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2050-2052.	1.3	33
79	Asymmetry of the Regimen Is Correlated to Self-Reported Suboptimal Adherence: Results From AdUCSC, a Cohort Study on Adherence in Italy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 55, 411-412.	0.9	11
80	Treatment Change in Pregnancy Is a Significant Risk Factor for Detectable HIV-1 RNA in Plasma at End of Pregnancy. <i>HIV Clinical Trials</i> , 2010, 11, 303-311.	2.0	21
81	Insulin resistance and HCV virologic response to peg-interferons (Peg-IFN) with ribavirin (RBV) in HIV/HCV co-infected patients. <i>Journal of Hepatology</i> , 2010, 52, 306-307.	1.8	3
82	Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin's lymphoma. <i>Aids</i> , 2010, 24, 2408-2412.	1.0	27
83	Plasma Lipid Profile in Pregnant Women with HIV Receiving Nevirapine. <i>AIDS Patient Care and STDs</i> , 2009, 23, 147-152.	1.1	2
84	Antiretroviral Treatment in Pregnancy: A Six-Year Perspective on Recent Trends in Prescription Patterns, Viral Load Suppression, and Pregnancy Outcomes. <i>AIDS Patient Care and STDs</i> , 2009, 23, 513-520.	1.1	39
85	Effect of HCV Infection on Glucose Metabolism in Pregnant Women with HIV Receiving HAART. <i>HIV Clinical Trials</i> , 2009, 10, 403-412.	2.0	6
86	Genotypic Resistance Profile and Clinical Progression of Treatment-Experienced HIV Type 1-Infected Patients with Virological Failure. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 149-154.	0.5	19
87	Factors Influencing Gestational Age-Adjusted Birthweight in a National Series of 600 Newborns from Mothers with HIV. <i>HIV Clinical Trials</i> , 2008, 9, 287-297.	2.0	11
88	Trough Concentrations of Lopinavir, Nelfinavir, and Nevirapine With Standard Dosing in Human Immunodeficiency Virus-Infected Pregnant Women Receiving 3-Drug Combination Regimens. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 604-610.	1.0	8
89	HIV RNA viral Load and CD4 ⁺ T-cell Counts in HIV-Infected Pregnant Women with and without Treatment Discontinuation in Early Pregnancy. <i>Antiviral Therapy</i> , 2008, 13, 519-527.	0.6	2
90	Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: Prevalence and predictors. <i>Scandinavian Journal of Infectious Diseases</i> , 2007, 39, 813-818.	1.5	3

#	ARTICLE	IF	CITATIONS
91	Pregnancy outcomes and antiretroviral treatment in a national cohort of pregnant women with HIV: overall rates and differences according to nationality. BJOG: an International Journal of Obstetrics and Gynaecology, 2007, 114, 896-900.	1.1	6
92	Lipid Profile During Pregnancy in HIV-Infected Women. HIV Clinical Trials, 2006, 7, 184-193.	2.0	12